NCT01417052 - A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Rheumatoid Arthritis

Interventions

DRUG

50 mg LX3305 QD

50 mg LX3305 once daily in capsule form

DRUG

100 mg LX3305 QD

100 mg LX3305 once daily in capsule form

DRUG

150 mg LX3305 QD

150 mg LX3305 once daily in capsule form

DRUG

200 mg LX3305 QD

200 mg LX3305 once daily in capsule form

DRUG

250 mg LX3305 QD

250 mg LX3305 once daily in capsule form

DRUG

300 mg LX3305 QD

300 mg LX3305 once daily in capsule form

DRUG

400 mg LX3305 QD

400 mg LX3305 once daily in capsule form

DRUG

250 mg LX3305 BID

250 mg LX3305 twice daily in capsule form

DRUG

500 mg LX3305 QD

500 mg LX3305 once daily in capsule form

DRUG

Placebo

Matching placebo dosing in capsule form

Trial Locations (1)

Lexicon Investigational Site, Dallas